Authors: Karimi A, Naeini F, Azar VA, Hasanzadeh M PMID: 33940332 DOI: 10.1016/j.phymed.2021.153567 Abstract Background: Sepsis is a life-threatening condition caused by a dysregulated host response to infection. Several studies have indicated that flavonoids exhibit a wide variety of biological actions including free radical scavenging and antioxidant activities. Quercetin, one of the most extensively distributed [...]

Authors: Schroeder S, Hofer S, Zimmermann A, Pechlaner R, Pendl T, Bergmann M et al. PMID: 33852843 DOI: 10.1016/j.celrep.2021.108985 Abstract Decreased cognitive performance is a hallmark of brain aging, but the underlying mechanisms and potential therapeutic avenues remain poorly understood. Recent studies have revealed health-protective and lifespan-extending effects of dietary spermidine, a natural autophagy-promoting polyamine. [...]

Authors: Saha JK, Raihan J PMID: 33867777 PMCID: PMC8039806 DOI: 10.1007/s11224-021-01776-0 Abstract In this study, we have investigated the binding mechanism of two FDA-approved drugs (ivermectin and levosalbutamol) with the spike protein of SARs-CoV-2 using three different computational modeling techniques. Molecular docking results predict that ivermectin shows a large binding affinity for spike protein (− [...]

Authors: Theoharides TT, Cholevas C, Polyzoidis K, Poliotis A PMID: 33847020 PMCID: PMC8250989 DOI: 10.1002/biof.1726 Abstract COVID-19 leads to severe respiratory problems, but also to long-COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long-COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or [...]

Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.

Authors: Bello M PMID: 33843474 PMCID: PMC8054936 DOI: 10.1080/07391102.2021.1911857 Abstract Ivermectin (IVM) is an FDA-approved drug that has shown antiviral activity against a wide variety of viruses in recent years. IVM inhibits the formation of the importin-α/β1 heterodimeric complex responsible for the translocation and replication of various viral species proteins. Also, IVM hampers SARS-CoV-2 replication [...]

Authors: Ranjbar K, Shahriarad R, erfani A, Khodamoradi Z, Saadi MH PMID: 33838657 PMCID: PMC8035859 DOI: 10.1186/s12879-021-06045-3 Abstract Background: Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the [...]

Authors: Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C et al. PMID: 33844996 PMCID: PMC8040526 DOI: 10.1016/S2213-2600(21)00160-0 Abstract Background: Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that the widespread use of inhaled glucocorticoids [...]

Authors: Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J PMID: 33833065 PMCID: PMC8666823 DOI: 10.1136/gutjnl-2021-324090 Abstract We read with great interest the recent article published in Gut in which Yeoh et al demonstrated that gut microbiota composition of recovered patients with COVID-19 remained significantly distinct from uninfected controls. Persisting symptoms, also [...]

Authors: Rashid RA, Zgair A, Al-Ani R PMID: 33839489 PMCID: PMC8024226 DOI: 10.1016/j.amjoto.2021.103033 Abstract Objectives: Anosmia is a common debilitating symptom of the novel coronavirus disease 2019 (COVID-19). Currently, there is no satisfactory treatment of anosmia. Therefore, this study was conducted to evaluate the therapeutic effect of nasal betamethasone drops in the recovery of olfaction [...]